Estimation of Serum TLR-9,TNF-α, and IL-6 Levels in the Iraqi Patients Diagnosed as Acute Myelogenous Leukemia
DOI:
https://doi.org/10.21123/bsj.2023.9056Keywords:
Acute Myeloid Leukemia (AML), Toll-Like Receptor-9 (TLR-9), Interleukin-6 (IL-6), Tumor Necrosis Factor Alpha (TNF-α), Tumor Microenvironment (TME), Acute Promyelocytic Leukemia (APL)Abstract
Acute myelogenous leukemia (AML) is a varied group of biological and clinical diseases. It is distinguished by the fast proliferation of aberrant cells in the bone marrow, which interferes with normal blood cell formation. Several studies demonstrated that cytokines released by leukemic cells in an autocrine or paracrine manner influence the proliferation of AML cells. Our study aimed to assess serum levels of TLR-9, TNF-α and, IL-6 in patients of AML. The study was done via the ELISA Technique. The results show a highly significant difference in all parameters in Patients and control. The correlation between immunological parameters using the Pearson correlation coefficient for patients showed that there is a weak correlation between TLR-9 and TNF- α, IL-6 with P-values of 0.47 and 0.23 respectively. This may indicate the complex environment of inflammation. However, there was a strong correlation between TNF- α and IL-6 with a P-value (0.001). This indicates that the secretion of these cytokines was high in patients. All immunological parameters of patients were evaluated using the receiver operating characteristic (ROC) curve to demonstrate that any one of them is a useful tool for identifying and tracking inflammation. The ROC curve's findings revealed that all parameters have good sensitivity and specificity for detecting inflammation and disease activity in AML patients. According to the current study, AML was related to higher levels of TLR-9, TNF-α, and, IL-6 may be affected the prognosis of the disease, increase the risk of the disease progression, and may be used as a biomarker to target AML cells.
Received 11/05/2023
Revised 28/07/2023
Accepted 30/07/2023
Published Online First 25/12/2023
References
Lowenberg B, Downing J R, Burnett A. Acute myeloid leukemia. N Engl Med. 1999; 341(14): 1051-1062. https://doi.org/10.1056/nejm199909303411407
Sepehrizadeh Z, Mohammadi M, Emami A, Yazdi M T, Bozchlou S H, Khorramizadeh M R, et al. Assessment of cytokine expression profile in acute myeloid leukemia patients before and after chemotherapy. Turk J Hematol. 2014; 31(2): 149. https://doi.org/10.4274/ijh_2012.0164
Siveen K S, Uddin S, Mohammad R M. Targeting acute myeloid leukemia stem cell signaling by natural products. Mol cancer. 2017; 16: 1-12. https://doi.org/10.1186/s12943-016-0571-x
Tettamanti S, Pievani A, Biondi A, Dotti G, Serafini M. Catch me if you can: How AML and its niche escape immunotherapy. Leukemia. 2022. 36(1): 13-22. https://doi.org/10.1038/s41375-021-01350-x
Tahmasebi S, Alimohammadi M, Khorasani S, Rezaei N. Pro-tumorigenic and Anti-tumorigenic Roles of Pro-inflammatory Cytokines in Cancer. In Handbook of Cancer and Immunology. 2022; pp. 1-25. Cham: Springer Int Publishing. https://doi.org/10.1007/978-3-030-80962-1_25-1
Cui X, Zhang H, Cao L, Hu X. Cytokine TNF-α promotes invasion and metastasis of gastric cancer by down-regulating Pentraxin3. J Cancer.2020; 11(7): 1800. https://doi.org/10.7150%2Fjca.39562
Verma S, Singh A, Yadav G, Kushwaha R, Ali W, Verma S. P, et al. Serum Tumor Necrosis Factor-Alpha Levels in Acute Leukemia and Its Prognostic Significance. Cureus. 2022; 14(5):e24835. https://doi.org/10.7759%2Fcureus.24835
Tian T, Wang M, Ma D. TNF-α, a good or bad factor in hematological diseases?. Stem Cell investig. 2014; 1: 12. https://doi.org/10.3978%2Fj.issn.2306-9759.2014.04.02
Zhou X, Li Z, Zhou J. Tumor necrosis factor α in the onset and progression of leukemia.Exp Hematol.2017; 45: 17-26. https://doi.org/10.1016/j.exphem.2016.10.005
Cai X, Cao C, Li J, Chen F, Zhang S, Liu B, et al. Inflammatory factor TNF-α promotes the growth of breast cancer via the positive feedback loop of TNFR1/NF-κB (and/or p38)/p-STAT3/HBXIP/TNFR1. Oncotarget. 2017; 8(35): 58338. https://doi.org/10.18632/oncotarget.16873
Kadhum M S, Abdullah A R, Shabeeb Z A. Estimation of the IL-6 serum level in the Iraqi newly diagnosed AML patients. Teikyo Med. J. . 2022; 45(01): 1-5.
Camacho V, Kuznetsova V, Welner R S. Inflammatory cytokines shape an altered immune response during myeloid malignancies. Front Immunol. 2021; 12: 772408. https://doi.org/10.3389/fimmu.2021.772408.
Dawood S D. Assessment of IL-6 serum level in patients with acute myeloid leukemia. Iraqi J Cancer Med Genet. 2011; 4: 22-8. https://ijcmg.uomustansiriyah.edu.iq/index.php/ijcmg/article/download/51/33
West N R. Coordination of immune-stroma crosstalk by IL-6 family cytokines. Front Immunol. 2019; 10: 1093. https://doi.org/10.3389/fimmu.2019.01093.
Sariani O K, Eghbalpour S, Kazemi E, Buzhani K R, Zaker F. Pathogenic and therapeutic roles of cytokines in acute myeloid leukemia. Cytokine. 2021; 142: 155508. https://doi.org/10.1016/j.cyto.2021.155508
Monlish D A, Bhatt S T, Schuettpelz L G. The role of toll-like receptors in hematopoietic malignancies. Front Immunol. 2016; 7: 390. https://doi.org/10.3389/fimmu.2016.00390
Fabricius D, Breckerbohm L, Vollmer A, Queudeville M, Eckhoff S M, Fulda S, et al. Acute lymphoblastic leukemia cells treated with CpG oligodeoxynucleotides, IL-4 and CD40 ligand facilitate enhanced anti-leukemic CTL responses. Leukemia. 2011; 25(7): 1111-1121. https://doi.org/10.1038/leu.2011.87
George-Gay B, Parker K. Understanding the complete blood count with differential. J Perianesth Nurs. 2003; 18(2): 96-117. https://doi.org/10.1053/jpan.2003.50013
Al-Husseiny A H. Acute myeloid leukemia in adolescent and adult Iraqi patients clinical and hematological study. Diala J. 2008; 29: 1-11. https://www.iasj.net/iasj/article/17742
Ahmed H A, Maklad A M, Khaled S A, Elyamany A. Interleukin-27 and interleukin-35 in de novo acute myeloid leukemia: expression and significance as biological markers. J Blood Med. 2019; 10: 341. https://doi.org/10.2147/JBM.S221301
Sanchez-Correa B, Bergua J M, Campos C, Gayoso I, Arcos M J, Bañas H, et al. Cytokine profiles in acute myeloid leukemia patients at diagnosis: survival is inversely correlated with IL-6 and directly correlated with IL-10 levels. Cytokine. 2013; 61(3): 885-891. https://doi.org/10.1016/j.cyto.2012.12.023
Ahmed H S, Tahir N T, Obed F A. Cytokines profiling as prognostic markers in newly diagnosed acute myeloid leukemia. Iraqi J Hematol.. 2017; 6(2). https://doi.org/10.4103/ijh.ijh_20_17
Tsimberidou A M, Estey E, Wen S, Pierce S, Kantarjian H, Albitar M, et al. The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high‐risk myelodysplastic syndromes. Cancer. 2008; 113(7): 1605-1613. https://doi.org/10.1002/cncr.23785
Wang M, Zhang C, Tian T, Zhang T, Wang R, Han F, et al. Increased regulatory T cells in peripheral blood of acute myeloid leukemia patients rely on the tumor necrosis factor (TNF)-α–TNF receptor-2 pathway. Front Immunol. 2018; 9:1274. https://doi.org/10.3389%2Ffimmu.2018.01274
Mustafa R A, Jasim H A, Al-Salait S K. A. Quantitative Determination of Serum Level of TLR4, TLR7, and TLR9 in Pediatric Acute Lymphoblastic Leukemia (ALL) Patients in Basrah, Iraq. Biomed Pharma J. 2021; 14(4): 2255-2260. https://dx.doi.org/10.13005/bpj/2325
Abdulwahid A G, Abdullah H N. Expression of Serum IL-22, IL-23, and TLR9 as Tumor Markers in Untreated Breast Cancer Patients. Int J Drug Deliv Sci Technol. 2020; 10(03): 472-476. http://dx.doi.org/10.25258/ijddt.10.3.30
Ilvesaro J M, Merrell M A, Li L, Wakchoure S, Graves D, Brooks S, et al Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion. Mol Cancer Res. 2008; 6(10): 1534–1543. https://doi.org/10.1158/1541-7786.MCR-07-2005.
Sandholm J, Selander K S. Toll-like receptor 9 in breast cancer. Front Immunol.2014; 5: 330. https://doi.org/10.3389/fimmu.2014.00330
Lu C C, Kuo H C, Wang F S, Jou M H, Lee K C, Chuang J H. Upregulation of TLRs and IL-6 as a marker in human colorectal cancer. Int J Mol Sci. 2014; 16(1): 159-177. https://doi.org/10.3390/ijms16010159
Ahmed M F, Salih S M. Impact of Toll-Like Receptors 7 and 9 and Tumor Necrosis Factor-alpha in Iraqi Patients with Urinary Bladder Carcinoma. Int J Drug Deliv Sci Technol. 2021; 11(1): 109-112. http://impactfactor.org/PDF/IJDDT/11/IJDDT,Vol11,Issue1,Article20.pdf
Al-Kahiry W, Dammag E A, Abdelsalam H S, Fadlallah H K, Owais M S. Toll-like receptor 9 is negatively related to the clinical outcome of AML patients. J Egypt Natl Canc Inst.2020; 32(1):1-7. https://doi.org/10.1186/s43046-020-00027-3
Cytokines and Their Side Effects, online website (2019).https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/cytokines.html
Panezai J, Ghaffar A, Altamash M, Sundqvist KG, Engström P E, Larsson A. Correlation of serum cytokines, chemokines, growth factors, and enzymes with periodontal disease parameters. PloS one.2017;12(11): e0188945. https://doi.org/10.1371%2Fjournal.pone.0188945
Downloads
Issue
Section
License
Copyright (c) 2023 Baghdad Science Journal
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
